Brompheniramine hydrogen maleate

Research use only, not for human use.

Brompheniramine maleate is a histamine H1 receptors antagonist.

Brompheniramine maleate is a histamine H1 receptors antagonist. (In Vitro):Brompheniramine (0.1-100 μM) blocks hERG K+ channels expressed in CHO cells in a concentration-dependent manner with an IC50 of 0.90±0.14 μM, and reduced peak tail current amplitude measured at -60 mV (cells are depolarized for 2 s to +20 mV from a holding potential of -80 mV followed by a 3s repolarization back to -60 mV).Brompheniramine (1, 10 and 100 μM) significantly shortens the APD50 and depresses the plateau phase on the action potential in guinea pig papillary muscle, as well as slightly prolongs the APD90 in guinea pig papillary muscle at 10 and 100 μM.Brompheniramine (0.1-100 μM) inhibit the amplitude of the Ca2+ channel currents in rat ventricular myocytes by 14.1±1.1, 31.1±5.8, 38.0±3.8 and 90.2±3.7% at 0.1, 1, 10 and 100 μM, respectively.Brompheniramine blocks muscarinic cholinergic receptors in human chinese hamster ovary (CHO) cells.(In Vivo):Brompheniramine (0.3-3?μM; SC, single dosage) induces cutaneous analgesia in rats.

Brompheniramine (0.1-100 μM) blocks hERG K+ channels expressed in CHO cells in a concentration-dependent manner with an IC50 of 0.90±0.14 μM, and reduced peak tail current amplitude measured at -60 mV (cells are depolarized for 2 s to +20 mV from a holding potential of -80 mV followed by a 3s repolarization back to -60 mV).Brompheniramine (1, 10 and 100 μM) significantly shortens the APD50 and depresses the plateau phase on the action potential in guinea pig papillary muscle, as well as slightly prolongs the APD90 in guinea pig papillary muscle at 10 and 100 μM.Brompheniramine (0.1-100 μM) inhibit the amplitude of the Ca2+ channel currents in rat ventricular myocytes by 14.1±1.1, 31.1±5.8, 38.0±3.8 and 90.2±3.7% at 0.1, 1, 10 and 100 μM, respectively.Brompheniramine blocks muscarinic cholinergic receptors in human chinese hamster ovary (CHO) cells.

Brompheniramine (0.3-3?μM; SC, single dosage) induces cutaneous analgesia in rats. Animal Model:Male Sprague-Dawley rats Dosage:0.3, 0.6, 1.1, 1.5 and 3.0 ?μM Administration:SC, single dosage Result:Provoked cutaneous analgesia in a dose-dependent manner, with an EC50 value of 0.66 μM, and induced prolonged analgesic duration.

(±)-Brompheniramine

Endocrinology/Hormones

5-HT Receptor

HT

Inflammation/Immunology

——

980-71-2

435.31

C16H19BrN2·C4H4O4

>98% (HPLC)

Ethanol: 18 mg/mL (41.34 mM); Water: 46 mg/mL warmed (105.67 mM); DMSO: 87 mg/mL (199.85 mM)

CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years